Genomic profiles reveal the mechanism of PD-L1-induced resistance to EGFR-TKIs in lung adenocarcinoma
China National GeneBank DataBase · 02.07.2026
DOI: 10.26036/cnp0005864 ↗Kurz gefasst
Fachartikel in der Zeitschrift China National GeneBank DataBase, erschienen am 02.07.2026. Verfasst von 李诗芊(Hester).
Abstract (Originalsprache)
Concurrent presence of PD-L1-positive and activating epidermal growth factor receptor (EGFR) mutations in advanced Non-Small Cell Lung Cancer (NSCLC) typically results in restricted effectiveness of EGFR-tyrosine kinase inhibitors (EGFR-TKIs), and the underlying mechanism remains unidentified. We enrolled 103 EGFR-mutant LUAD patients, evaluating PD-L1 expression and conducting Next-generation sequencing (NGS) for gene mutation analysis. This study elucidates the molecular mechanism of PD-L1-induced primary resistance to EGFR-TKI. Nevertheless, for patients with concurrent mutations in EGFR and PD-L1 expression, a first-line treatment strategy that combines EGFR-TKI with chemotherapy may provide a more potent alternative.
Schlagwörter
Zitieren
APA
李诗芊(Hester) (2026). Genomic profiles reveal the mechanism of PD-L1-induced resistance to EGFR-TKIs in lung adenocarcinoma. China National GeneBank DataBase. https://doi.org/10.26036/cnp0005864
Vancouver
李诗芊(Hester). Genomic profiles reveal the mechanism of PD-L1-induced resistance to EGFR-TKIs in lung adenocarcinoma. China National GeneBank DataBase. 2026. doi:10.26036/cnp0005864
BibTeX
@article{Hester2026,
author = {李诗芊(Hester)},
title = {Genomic profiles reveal the mechanism of PD-L1-induced resistance to EGFR-TKIs in lung adenocarcinoma},
journal = {China National GeneBank DataBase},
year = {2026},
doi = {10.26036/cnp0005864}
}
EUVIMED